Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers

Nuclear Medicine Communications

Volumn 25, Issue 12, 2004, Pages 1183-1186

  Philips, Jean Christophe ^a   Petite, Christophe ^a   Willi, Jean Pierre ^a   Buchegger, Franz ^a   Meier, Christoph A ^a  

^a Department of Internal Medicine   (United States)

Author keywords

Cancer; Redifferentiation; Rosiglitazone; Thyroid

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RECOMBINANT THYROTROPIN; ROSIGLITAZONE; THYROGLOBULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EDEMA; HUMAN; LIVER DISEASE; LUNG METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; THYROID CANCER;

ADULT; AGED; CELL DIFFERENTIATION; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PPAR GAMMA; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; THYROGLOBULIN; THYROID NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 10144233475     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200412000-00005     Document Type: Article

References (10)

1. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
2. Goretzki PE, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid cancer. Br J Surg 1993; 80:1009-1012.
3. Hinds T, West W, Knight E. Carotenoids and retinoids: a review of research, clinical and public health applications. J Clin Pharmacol 1997; 37:551-558.
4. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002; 29:775-782.
5. Grunwald F, Menzel C, Bender H. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39:1903-1906.
6. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000; 21:469-474.
7. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA 2000; 97:10-990-10-995.
8. Ohta K, Endo T, Haraguchi K, Hershman J, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:2170-2177.
9. 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41:1010-1015.
10. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001; 42:1464-1469.